| Reference/ Number of Patients | Outcomes | 3 months | 6 months | 12 months | Comments |
|---|---|---|---|---|---|
| Bales 3 1995 | Negative biopsy | 19/22 (86%) | 13/22 (59%) | ||
| 23 | |||||
| PSA<0.3ng/mLa | 8/22 (36%)b | 3/22 (14%) | 11%±7% (17months) | ||
| Miller 2 1996 | Negative biopsy | 15/22 (68%) | |||
| 33c | |||||
| PSA<0.4ng/mLd | 6/22 (27%) | 3/10 (33%)e | |||
| Pisters 6 1997 | 29/41 (71%) | SFTCi | |||
| 110f | Negative biopsy | 67/82h (82%) | |||
| 38/41 (93%) | DFTCj | ||||
| Undetectable <0.1 | 40/108 (37%) | PSA increase | 18/51 (35%) | SFTC>i | |
| ng/mL nadir PSA | <0.2 ng/ml | ||||
| above nadir | |||||
| PSA levelg | 32/57 (56%) | DFTCj | |||
| Schmidt 21 1998 | Negative biopsy | 18/21 (86%) | |||
| 21 | No perioperative | ||||
| PSA normal rangek | 14/21 (67%) | deaths | |||
| PSA undetectablek | 6/14 (40%) | ||||
| Von Eschenbach 20 | 69% | SFTCi | |||
| 1995 | Negative biopsy | 52/67 (78%) | |||
| 89 | 92% | DFTCj | |||
| Undetectable PSA levels | 17/67 (25%) | Results similar for SFTC & DFTC | |||
Biochemical cure.
PSA declined in 18/22 patients.
Eleven patients were on androgen suppressive therapy.
Biochemical cure.
Of 10 patients with a negative biopsy for at least 1 year.
Prior radiation therapy only in 110/150 prostate cancer patients.
Biochemical cure. PSA data available for 108 patients.
Biopsy results were available in 82/110 patients.
Single freeze-thaw cycle.
Double feeze-thaw cycle.
Not defined.
From: Cryosurgery for Recurrent Prostate Cancer Following Radiation Therapy
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.